Rodents treated with 150 mg/kg of 5fluorouracil (5FU) exhibit a marked and prolonged rebound thrombocytosis, suggesting that feedback control of one or more megakaryocyte characteristics (size. polyploidy, or concentration) is altered. To determine the changes in megakaryocytes that lead to such a profound thrombocytosis. C3H mice were injected with 150 mg/kg 5FU. and platelet and megakaryocyte responses were examined at frequent intervals from days 1 through 25. After 5 F U injection. all megakaryocyte indices decreased, as did platelet number. However, the decrease in platelets to one third of control was greater than the decreases in megakaryocyte indices, suggesting that thrombocytopoiesis was ineffective from days 3 through 7 post 5FU. Megakaryocyte size began to recover on day 4. followed by polyploid DNA content on day 5, and megakaryocyte concentration and platelets at 7.5 days.
a close inverse relationship to platelet counts during both the recovery and rebound thrombocytosis phases after 5FU. In contrast, megakaryocyte size peaked before platelet recovery commenced, while megakaryocyte concentration increased in parallel with platelets from 7.5 to 10 days post 5-FU and continued to be maintained at 2 to 3 times normal through day 13. despite platelet levels that were more than twice normal. Both megakaryocyte size and polyploid DNA content distributions shifted toward lower values in response to the rebound thrombocytosis (DNA content on day 10 and size on days 12 and 13). Splenectomy did not substantially alter the pattern of post 5FU rebound thrombocytosis or megakaryocyte response from that seen in intact mice, indicating that splenic megakaryocytes are not responsible for the prolonged thrombocytosis seen after this drug. In summary, the prolonged thrombocytosis after 5-FU administration results from failure to down-regulate the number of precursors entering the differentiating megakaryocyte compartment. These data indicate that megakaryocyte size and DNA content are responsive to different feedback controls than megakaryocyte concentration in this model system. 0 1990 by The American Society of Hematology. ~o n t e n t .~~.~~ All of these megakaryocyte parameters are thought to be regulated in some way by platelet demand.8s'0*3035 Thus, a likely explanation for the exaggerated thrombocytosis is that the feedback control normally exerted on megakaryocytopoiesis by elevated platelet numbers is disrupted in the 5-FU-treated mouse.2'*28 Several intriguing observations have been made concerning megakaryocytopoiesis after 5-FU. For instance, Radley and S c~r f i e l d~~ reported that megakaryocytopoiesis recovered faster than granulopoiesis and erythropoiesis, and that megakaryocytes were the dominant marrow cell on day 7 post 5-FU. Radley et subsequently reported that marrow megakaryocyte concentration, assessed at 2-to 3-day intervals, was highest on day 7 (more than four times that of untreated controls), while splenic megakaryocyte concentration was highest on days 17 and 19. In that same study, megakaryocyte size was evaluated at two time intervals: marrow megakaryocytes were larger on day 7, but smaller on day 17 post 5-FU compared with thoseof untreated controls.27 However, insufficient time points were examined to dissect out relationships between megakaryocyte size and number and platelet counts, except that the increase in splenic megakaryocytes occurred a t the same time as the thrombocytosis. In a related study, Yeager et a128 reported that splenic megakaryocyte colony-forming cells (Meg-CFC) rose to 2,000% to 2,500% of control from days 11 through 17 before returning to baseline by day 20 (marrow Meg-CFC did not increase above normal). This suggested that splenic thrombocytopoiesis may play a major role in producing the marked and prolonged thromb Jcytosis. The present study was designed to: (1) detail tl ; post 5-FU megakaryocyte response to delineate relationships among the various megakaryocyte indices and platelet counts, both early, and during and after recovery; and (2) to evaluate the contribution of splenic megakaryocytes to the thrombocytosis with the goal that the results would: (A) provide insight into the cause of the exaggerated thrombocytosis in this experimental model and (B) increase our understanding of the regulation of megakaryocytopoiesis.
MATERIALS AND METHODS
Twelve-to 27-week-old female C3H/HEN mice, from Charles River Laboratories (Wilmington, MA), were injected with 5-FU, 150 mg/kg of body weight (SoloPak Laboratories, Franklin Park, IL). Control mice were either injected with saline or untreated. All mice were injected between 9:OO AM and noon, were allowed free access to food and water, and were housed in the same room with a 12-hour day/night cycle. The specimens described below were collected daily from days 1 through 20 after 5-FU injection and also at 7.5,8.5,22, and 25 days. Samples from at least one control mouse were obtained at each sample time.
Most mice were splenectomized at 3 weeks of age. At the time of 5-FU injection, these splenectomized mice were I5 weeks old. Some mice were splenectomized at 10 weeks of age and given 5-FU at 23 weeks of age. Specimens were obtained from each of three splenectomized mice at 7,9,10,12,15,17, and 20 days post 5-FU. Twelve-week-old intact mice were injected with 5-FU and killed in parallel. Controls were untreated splenectomized and intact mice of the same age. Twenty-microliter blood samples were obtained by puncture of a tail vein after vasodilation induced by warming the mice under an examination lamp. Ten-microliter blood samples were obtained when the platelet counts were above 1.5 x 106/mm3. All samples were diluted in 1% ammonium oxalate solution (Unopette Microdilution System; Becton-Dickinson, Rutherford, NJ) for platelet enumeration by phase microscopy.
Sternums were fixed in B5 fixative, decalcified, embedded in paraffin, sectioned at 5 pm, and the sections stained with hematoxylin and eosin. Megakaryocytes were identified by their large size, large lobulated nuclei with thick, clumped, deeply basophilic staining nuclei and abundant cytoplasm. The diameters of megakaryocytes (usually 50 per mouse) were measured in the marrow sections by a computer-assisted image analysis system. Megakaryocyte concentration, mitotic index, and differential. The average number of megakaryocytes per high power field (HPF) ( 1 2 . 5~ ocular, 40x objective, field diameter = 0.3 mm) was determined in one entire 5-pm thick section of each sternum. To estimate megakaryocyte concentration, the megakaryocytes/HPF value for each mouse was corrected for multiple counting error" resulting from treatment-related changes in megakaryocyte size by dividing this measurement by the quotient of the median megakaryocyte diameter for that animal divided by the average median diameter of uninjected control mice.
The number of megakaryocyte mitotic figures and degenerating megakaryocytes in the sternal sections were also quantitated. Degenerating megakaryocytes were defined as those having highly condensed nuclei without cytoplasm or with only a thin rim (less than 1 r m ) of acidophilic cytoplasm. Degenerating megakaryocytes with a thin rim of cytoplasm were distinguished from immature megakaryocytes by their condensed nucleus and acidophilic cytoplasm.
Megakaryocyte DNA distributions. Marrow megakaryocyte DNA distributions were determined by the two-color flow cytometric technique reported by Jackson et Marrow from one femur and one tibia was flushed with 0.5 mL CATCH medium39 with 20 U/mL DNase 140 into plastic tubes. The cells were suspended by Splenectomized mice.
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gentle pipetting with a plastic or siliconized glass pipette and kept on ice. The marrow suspension was filtered through 53 pm nylon mesh on days 5 and 15 through 20, and through 74 pm nylon mesh on all other days to remove large cell clumps. The larger poresized nylon mesh was used as a precautionary measure at time points when megakaryocytes were the largest, to ensure that large megakaryocytes would not be removed by this tiltration step. Megakaryocytes were labeled for 30 minutes on ice with platelet-specific rabbit anti-mouse platelet serum (RAMPS, gift of D r Ted McDonald) at a saturating concentration. The cells were next washed and pelleted (5 minutes at 182g) twice in 3 mL of CATCH medium at 4OC. The cells were then suspended in either 1 or 3 mL of CATCH medium, incubated with a saturating concentration of FlTC-labeled F(ab'), fragments of goat anti-rabbit immunoglobulin G (IgG; Tag0 Inc, Burlingame, CA) on ice for 30 minutes, and washed twice with CATCH medium. Finally, each sample was suspended in 3 mL propidium iodide in hypotonic citrate solution (0.05 mg/mL in 0.1% sodium citrate4'). The samples were stored at 4% until analysis later the same day or, in a few instances, the next morning. The samples were treated with RNase (bovine pancreas, 50 pg/mL, Calbiochem Corp, San Diego, CA) for 30 minutes at room temperature before flow cytometric analysis." An Epics 753 flow cytofluorometer (Coulter Electronics, Inc, Hialeah, FL) was configured and the samples analyzed as previously described.38
Statistical analyses. Statistical analyses were performed using a STATGRAPHICS statistical program (Statistical Graphics Corp, Inc, Rockville, MD). The Mann-Wbitney rank sum test was used to compare values from each day to control. Throughout the report, significance indicates a Pvalue <.OS.
RESULTS

Controls.
No significant differences were found between untreated and saline-injected controls in any characteristic examined. Throughout this report, control refers to untreated mouse values.
Platelet counts. Platelet counts decreased to about 30% of control by day 4 post 5-FU and were significantly decreased from days 4 through 8 (Fig 1) . Platelets first showed recovery at 7.5 days, reached normal at 8.5 days, and peaked at 2.3 times normal on day 12. Significant increases in platelets were present from days 10 through 18 post 5-FU. Megakaryocyte concentration. Megakaryocyte concentration was significantly decreased on day 2, had returned to normal levels on day 3, and was significantly decreased again on days 5 and 6 (Fig 2) before becoming significantly elevated (from days 8 through 13) with a peak of 3.6 times control on day 12. Day 25 was also significantly above control.
A shift to smaller megakaryocytes occurred on days 2 and 3 with recovery to a normal distribution by day 4 (Fig 3) . Megakaryocyte size distribu-
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tions were shifted to the right on days 5 through 8 with larger than normal megakaryocytes. By day 9, the size distribution had returned to normal, but on days 12 and 13 the distribution again showed an increase in smaller megakaryocytes. The size distributions were normal from day 14 onward.
The DNA distributions in untreated mice agree with those of earlier work from this lab42*43 indicating that the modal DNA content of normal C3H mouse megakaryocytes is 32N (as opposed to 16N in other mouse strains) ( Table 1) . Early after 5-FU injection, the proportions of higher ploidy cells decreased so that 8N became the modal megakaryocyte DNA class on day 4. Recovery in the proportions of 32N and 64N megakaryocytes and the appearance of 128N cells was apparent on day 5. The proportion of high ploidy (64N + 128N) megakaryocytes was maximally increased on day 8. On day 9, the DNA content distribution was shifting back toward normal. By day 10, 16N was the modal DNA class and remained so through day 20.
The proportion of megakaryocytes in endomitosis was significantly below control on days 1 and 2 (no endomitoses were detected on day 2), but rebounded quickly to a peak of 3.3 times normal on day 6 (Fig 4A) . The endomitotic index declined to a second nadir of 18% of control on day 12.
The concentration of megakaryocyte endomitoses (obtained by multiplying the endomitotic index by the corrected megakaryocytes/HPF) showed a slightly different pattern with a peak of 2.9 times normal occurring on day 8 (Fig 4B) , coinciding with the peak in high ploidy (greater than 32N) megakaryocytes ( Table 1) .
Megakaryocyte DNA content. Degenerating megakaryocytes. The concentration of degenerating megakaryocytes (percent degenerating megakaryocytes x corrected megakaryocytes/HPF) increased to a first peak on day 2 of 3.2 times control, followed by a decline to normal on day 7 and a second peak on days 9 and 10 of 4.3 times control before returning to normal on day 13 (Fig 5) .
Endomitotic index.
Eflect of splenectomy on the megakaryocyte and platelet response to 5-FU. With the exception of marginally higher (P = .052) platelet counts on day 15, the post 5-FU platelet decrease and rebound thrombocytosis of splenectomized mice were of a similar magnitude and duration as those of intact mice ( Table 2) , confirming the recent results of Ebbe et Although marginally significant differences (P = .052)
were seen in megakaryocyte concentration on day 15 and in DNA content distributions on days 12 and 17, overall, the post 5-FU megakaryocyte response of splenectomized mice was similar to that of intact mice ( Table 2) .
DISCUSSION
The marked and prolonged thrombocytosis in mice after administration of 5-FU is ~ell-documented''~'~-~~; however, the megakaryocyte changes that result in this unique response had not been rigorously defined. Here we have examined in detail the megakaryocyte response and evaluated which megakaryocyte parameters contribute to the post 5-FU thrombocytosis.
The decrease in endomitotic index to very low levels at 1 to 2 days suggests that a major effect of 5-FU was the killing of both late cycling progenitors and endomitotic megakaryocytes. Recovery of these compartments occurred rapidly since megakaryocyte endomitotic index increased from undetectable levels on day 2 to nearly normal on day 3. The rapid recovery of these compartments probably explains why megakaryocyte numbers were only moderately decreased. The early decrease in megakaryocyte size and DNA content probably reflects the exit of larger, mature megakaryocytes from the compartment with replacement by smaller, immature cells.
Despite only a modest decrease in megakaryocyte concentration in the first week after S F U , the platelet count decreased to one third of normal, suggesting that thrombopoiesis was ineffective during this period. Additional support for this interpretation is provided by comparisons of platelet counts after treatment of mice with hydroxyurea' and cycl~phosphamide.'*~ Although hydroxyurea and cyclophosphamide produced a decrease in megakaryocyte concentration comparable to that observed with 5-FU, the decrease in platelet count after 5-FU was much more profound and prolonged than with the other drugs, suggesting that platelets were not produced at the normal rate from days 3 through 7 after 5-FU. The explanation for this 5-FUinduced ineffective thrombocytopoiesis is not readily apparent. Both hydroxyurea and 5-FU kill cells in DNA synthesis; 1 through 3,8 .5, and 14 through 22, n = 4 days 5. 7. and 9, n = 6; days 6. 8. and 10 through 13, n = 7). (0) Saline-injected mice (n = 7). Seventy-four to 1,139 (median 260) megakaryocytes in 10 to 58 (median 27) high-power fields were examined for each mouse.
however, 5-FU is, in addition, incorporated into R N A and may interfere with R N A processing and/or t r a n~p o r t ?~ which in turn can lead to altered protein synthesis as well as further inhibition of DNA synthesis. The finding that megakaryocyte endomitotic index had recovered to normal by day 3 implies that inhibition of DNA synthesis was not responsible for decreased platelet production from days 4 through 7, and suggests that the prolonged thrombocytopenia results from effects of incorporation of 5-FU into RNA. This
0)
0.6 r C h possibility has been addressed indirectly by a recent study designed to metabolicly modulate 5-FU action. Although platelet counts were not performed a t frequent intervals, Peters et reported that injection of 3,500 mg/kg uridine at 2 and 20 hours post 5-FU when 100 mg/kg 5-FU was administered to mice on days 0 and 7, prevented the early thrombocytopenia and subsequent thrombocytosis seen in the group which received 5-FU alone. This uridine rescue protocol does not prevent the initial inhibition of thymidylate synthase (and decline in DNA synthesis), but accelerates the disappearance of 5-fluoro-uridine-5' triphosphate from R N A and the recovery of DNA Thus, Peters et al's study provides support for the hypothesis that the prolonged post 5-FU thrombocytopenia, which we attribute to ineffective thrombopoiesis, results from the effects of incorporation of 5-FU as 5-fluoro-uridine-5' triphosphate into RNA.
The explanation for the sustained thrombocytosis after 5-FU is an increase in marrow megakaryocyte concentration greater than that seen after single administration of other agents that produce a similar degree of thrombocytopenia, such as vincristine (0.5 mg/kg)' and thio-TEPA (triethylenethiophosphoramide, 10 mg/kg).47 With these latter agents, megakaryocytes showed a modest rebound overshoot, but quickly returned to baseline levels as platelet counts exceeded normal, so that only a short period of rebound thrombocytosis occurred. However, with 5-FU, megakaryocyte concentration continued to increase despite supranormal platelet levels, and was maintained a t three times normal from days 9 through 12. The explanation for the exaggerated and prolonged increase in megakaryocyte concentration post 5-FU remains unknown, but must be related to increased numbers of progenitors and/or elevated levels of growth factors.
Of interest regarding megakaryocyte progenitors is that the post 5-FU increase in marrow megakaryocytes was not preceded by an overshoot in in vitro-assayed marrow megakaryocyte colony-forming unit (CFU-MK)*'; however, another megakaryocyte progenitor, the megakaryocyte spleen colony-forming unit (MK-CFUS), measured in vivo by the 10-day spleen colony assay, was increased fourfold on day 7 post 5-FU?' which suggests that excessive proliferation of a On all other days, 5-FU-treated mice (number of mice per point was as follows: days 4-75, and 25, n = 3: days 1 through 3. 8.5. and 14 through 22, n = 4; days 5,7, and 9, n = 6: days 6. 8, and 10 through 13, n = 7). (0) On day 0, salineinjected mice (n = 7). Seventy-four to 1.1 39 (median 260) megakaryocytes in 10 to 58 (median 27) high-power fields were examined for each mouse. progenitor, more primitive than the CFU-MK assayed in vitro, is responsible for the exaggerated increase in marrow megakaryocytes post 5-FU.
In contrast to megakaryocyte concentration, megakaryocyte size and DNA content quickly down-regulated as platelet counts returned to normal, indicating that these two megakaryocyte parameters were responsive to platelet feedback regulation post 5-FU, while megakaryocyte concentration was not. Although the increase in megakaryocyte concentration was much more modest, a similar discordance between the response of megakaryocyte concentration, and size and DNA content was reported" during platelet recovery in a model of chronic thrombocytopenia (induced by multiple injections of platelet antiserum). These observations suggest that, in these two in vivo models, factors controlling megakaryocyte size and DNA content differ from those controlling megakaryocyte concentration. This is consistent with the two-factor hypothesis for regulation of megakaryocyte differentiation in vitro proposed by Williams et al;' in which one factor controls proliferation of megakaryocyte progenitors and thus, megakaryocyte number, while the second factor regulates megakaryocyte size and DNA content.
The data of Radley et a12' and Yeager et alZ8 suggested that splenic megakaryocytopoiesis may be responsible for the prolonged thrombocytosis; however, we found no substantial difference in the height or duration of thrombocytosis after 5-FU injection in splenectomized or intact mice, confirming a recently published report by Ebbe et al. 29 Likewise, the timing and degree of changes seen post 5-FU in marrow megakaryocyte concentration, size, and polyploid DNA content were similar in splenectomized and intact mice. Thus, although splenic megakaryocytes undoubtedly contribute platelets to the circulation, the platelet response of splenectomized mice indicates that splenic megakaryocytopoiesis is not a major contributor to the post 5-FU thrombocytosis.
We initiated these studies with 5-FU in C3H mice before learning that the modal megakaryocyte DNA content of C3H/HEN mice is 32N rather than 16N as in other mouse strains; however, the timing and extent of thrombocytosis after 5-FU in C3H mice appears similar to that previously reported for other mouse strains, suggesting that the major findings reported here would be applicable to other strains.
In summary, the prolonged thrombocytosis associated with hematopoietic recovery after 5-FU administration is due to exaggerated proliferation of megakaryocyte progenitors resulting in greatly increased megakaryocyte concentration, which is not immediately responsive to negative feedback regulation by elevated platelet counts. Splenic megakaryocytopoiesis does not contribute significantly to the prolonged thrombocytosis in this model. Our results indicate that megakaryocyte size and DNA content are under different regulation than megakaryocyte concentration in the 5-FU-treated mouse.
